Auto Component

North America was the largest market for healthcare, accounting for 41.9% of the global market in 2018. The fastest growing regions in the healthcare market will be the Asia Pacific and Africa, where growth will be at CAGRs of 13.4% and 13.1% respectively. The top opportunities in the global healthcare market will arise in the healthcare services segment which will gain $2,873.6 billion of global annual sales by 2022. Global sales from exported drugs and medicines by country totalled US$392.9 billion in 2019. Worldwide purchases of imported pharmaceutical drugs and medicines cost a total US$421.5 billion in 2019. The global market for generic drugs should reach $533 billion by 2021 from $352 billion in 2016 at a compound annual growth rate (CAGR) of 8.7%, from 2016 to 2021.

The pharmaceutical industry has seen rapid developments in terms of technology, innovation, and practices. Such changes can be attributed to rising patient awareness, increasing the cost of medicine, the entrance of medical insurers, and changes in rules and regulations.
The pharmaceutical industry will continue to witness major changes and challenges Such as global economic uncertainties, increasing healthcare costs and expiring patents, the industry. At the same time, Rapid development of the emerging markets, progress in drug research, the rise in generics production, the availability of high-potency drugs and innovations in manufacturing processes will sustainably modify the global pharmaceutical landscape.

The largest pharmaceutical industry mergers and acquisitions have been valued at many tens of billions of dollars. Pfizer’s takeover of Warner-Lambert tops the list at nearly $90 billion.3 The next closest surpassed the $70 billion market, including the recent acquisition of Celgene by Bristol-Myers Squibb (BMS), Aventis by Sanofi, and SmithKline Beecham by Glaxo. Several deals have been valued above $60 billion, including the recent acquisition of Allergan by AbbVie, transactions implemented by Pfizer with Pharmacia, and Wyeth and Takeda’s purchase of Shire.
Other deals in the $30 to $60 billion range include the acquisitions of Allergan by Actavis, Genentech by Roche, and Covidien by Medtronic.4 More recent deals worth noting include Teva Pharmaceutical’s purchase of Allergan’s generics division in 2015, Shire’s acquisition of Baxalta, Bayer’s purchase of Monsanto in 2016, and Johnson & Johnson’s takeover of Actelion in 2017.

Johnson & Johnson